NatRevUrol · 7 years ago
.@pcvblack – Tumour heterogeneity is the Achilles heel of targeted Rx. Few mutations shared by all tumour sites. Many just in primary or in Mets. ctDNA might help to overcome this limitation. #eau18
Get ready for the first HOT session in endouro for the day #EAU18 https://t.co/9Mm3UTKzwI
BCG shortages “frustrate” patients? Our feeling are significantly more than just frustration. Fear, ‘pushed’ into having RC. The shortages are a disgrace and should be headline news. ? #EAU18 https://t.co/szUDLzD270
The @OlympusUrology team is ready for a last exhibition day at the #EAU18 https://t.co/e5Avf3GXOt
#EAU18 #EAUN18 early start learning about the history and management of BCG in #bladdercancer chaired by @chats69 @GuysUrology https://t.co/XGMPKhfb0V
The UroNav Fusion Biopsy System from Invivo fuses prebiopsy MR images of the prostate with ultrasound-guided biopsy images in real time. Learn more at booth E73! #EAU18 https://t.co/mAodm2ZYWP
Tricky median lobe dissection durinh RRP @Uroweb @UrowebESU @EAUYAUrology #EAU18 #prostatecancer #urology https://t.co/mSfbWirCQG
Hamdy rebuttal: consider what the pt wants out of genetic testing. Philadelphia Consensus framework asks whether genetic tests should inform management. Shared decision making, test BRCA1/2, HOXB13, DNA MMR genes, ATM. More data required in AA men. Enrol in trials. #eau18 https://t.co/eYm3zqk1kc
Overview of gene testing for inherited PCa @Freddie_Hamdy #eau18 #pcsm https://t.co/9BWuw3FZYf
Moderate or vigorous physical activity reduces LUTS in 25%. #EAU18 https://t.co/nsAPf8YqAP